SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY
Diane V. Havlir
University of California San Francisco, San Francisco, CA, United States
INTRODUCTION OF PAUL LEHNER
Stuart J.D. Neil
King's College London, London, United Kingdom
HOW THE HUSH COMPLEX PROTECTS YOUR GENOME FROM RNA-DERIVED RETROELEMENTS (ABSTRACT
37)
Paul J. Lehner
Cambridge University, Cambridge, United Kingdom
INTRODUCTION OF GEORGE KUCHEL
Peter W Hunt
University of California San Francisco, San Francisco, CA, United States
THE SCIENCE OF AGING: LESSONS FOR HIV AT THE INTERFACE OF COMMONALITY AND HETEROGENEITY (ABSTRACT
38)
George A. Kuchel
University of Connecticut, Farmington, CT, United States
INTRODUCTIONS (Part 1)
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF (ABSTRACT
191)
Moti N. Ramgopal
Midway Immunology and Research Center, Fort Pierce, FL, United States
EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS (ABSTRACT
192)
Kathleen E. Squires
Merck & Co, Inc, North Wales, PA, United States
LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV (ABSTRACT
193)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION (ABSTRACT
194)
Marianne Martinello
University of New South Wales, Sydney, Australia
QUESTIONS AND ANSWERS (Part 1)
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV (ABSTRACT
195)
Emma Rubenstein
University of Paris Cité, Paris, France
SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL (ABSTRACT
196)
Jean-Michel Molina
University of Paris Cité, Paris, France
SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL (ABSTRACT
197)
Anthony M. Mills
Men's Health Foundation, Los Angeles, CA, United States
D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY (ABSTRACT
198)
Gail Matthews
University of New South Wales, Sydney, Australia
QUESTIONS AND ANSWERS (Part 2)
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
INTRODUCTIONS (Part 1)
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Francois Dabis
University of Bordeaux, Bordeaux, France
EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL (ABSTRACT
207)
Boghuma K. Titanji
Emory University, Atlanta, GA, United States
IMPACT OF VACCINATION ON MPOX INCIDENCE IN MSM ON PrEP IN THE ANRS 174 DOXYVAC TRIAL (ABSTRACT
208)
Jade Ghosn
University of Paris Cité, Paris, France
HOUSEHOLD TRANSMISSION OF MPOX TO CHILDREN AND ADOLESCENTS (ABSTRACT
209)
Darpun Sachdev
California Department of Public Health, San Francisco, CA, United States
ASSOCIATION BETWEEN OBSERVED MASKING AND SARS-CoV-2 PRESENCE IN SCHOOL WASTEWATER (ABSTRACT
210)
Rebecca Fielding-Miller
University of California San Diego, San Diego, CA, United States
QUESTIONS AND ANSWERS (Part 1)
Francois Dabis
University of Bordeaux, Bordeaux, France
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
INTRODUCTIONS (Part 2)
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Francois Dabis
University of Bordeaux, Bordeaux, France
VARIABLE REDUCTIONS IN SARS-CoV-2 VARIANT IMPORTATIONS FOLLOWING TRAVEL RESTRICTIONS (ABSTRACT
211)
Angela McLaughlin
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
INTERVENTION EFFICACY ON COVID-19 TESTING AND VACCINATION IN PEOPLE WHO INJECT DRUGS (ABSTRACT
212)
Angela R. Bazzi
University of California San Diego, La Jolla, CA, United States
CLUSTER-RANDOMIZED TRIAL COMPARING TWO SARS-CoV-2 TESTING MODELS IN AFRICA (ABSTRACT
213)
Nilesh Bhatt
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States
COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION (ABSTRACT
214)
Jing Sun
The Johns Hopkins University, Baltimore, MD, United States
QUESTIONS AND ANSWERS (Part 2)
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Francois Dabis
University of Bordeaux, Bordeaux, France
INTRODUCTIONS (Part 1)
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
Cynthia Derdeyn
University of Washington, Seattle, WA, United States
CD8+ T CELLS INDUCE HIV LATENCY IN CD4+ T CELLS THROUGH THE DOWNMODULATION OF NF-?B (ABSTRACT
174)
Simona Mutascio
Emory University, Atlanta, GA, United States
BLOCKING CD4+T CELL MIGRATION DELAYS VIRAL SPREAD FOLLOWING VAGINAL SIV CHALLENGE (ABSTRACT
175)
Claire Deleage
Frederick National Laboratory for Cancer Research, Frederick, MD, United States
DEPLETION OF SIV-SPECIFIC CD8+ T CELLS DOES NOT ALTER VIRAL LOAD DURING SIV INFECTION (ABSTRACT
176)
Jennifer Simpson
National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
PROTECTION AGAINST HTLV-1 CHALLENGE BY VACCINATION INDUCING ANTIBODIES IN MACAQUES (ABSTRACT
177)
Hiroshi Ishii
National Institute of Infectious Diseases, Tokyo, Japan
QUESTIONS AND ANSWERS (Part 1)
Cynthia Derdeyn
University of Washington, Seattle, WA, United States
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
SHIFTS IN SYSTEMIC INFLAMMATION AFTER FECAL MICROBIOTA TRANSPLANT IN PEOPLE WITH HIV (ABSTRACT
178)
Claudio Díaz-García
Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
AUTOLOGOUS NEUTRALIZING ANTIBODY RESPONSES IN bNAb-TREATED RHESUS MACAQUES (ABSTRACT
179)
Elise G. Viox
Emory University, Atlanta, GA, United States
ANALYSIS OF EPITOPE-SPECIFIC T CELLS IN SARS-CoV-2 INFECTION AND VACCINATION (ABSTRACT
180)
Kristin L. Boswell
National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
ANTI-PD-1 THERAPY INDUCED RAPID INNATE INTERFERON RESPONSES DRIVE HIV RESERVOIR DECAY (ABSTRACT
181)
Ashish Arunkumar Sharma
Emory University, Atlanta, GA, United States
SINGLE INFUSION OF STEM LIKE CCR5-MODIFIED CD4 T CELLS PROVIDE LONG-TERM HIV CONTROL (ABSTRACT
182)
Ana B. Enriquez
Emory University, Atlanta, GA, United States
QUESTIONS AND ANSWERS (Part 2)
Cynthia Derdeyn
University of Washington, Seattle, WA, United States
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
INTRODUCTIONS (Part 1)
Michael Corley
Weill Cornell Medicine, New York, NY, United States
Serena S. Spudich
Yale University, New Haven, CT, United States
SEX MODIFIES THE ASSOCIATION OF AGE AND VIREMIA WITH STROKE RISK IN HIV (ABSTRACT
183)
Felicia C. Chow
University of California San Francisco, San Francisco, CA, United States
INCREASED IMMUNE ACTIVATION IN HIV+ MSM ON ART, BUT NOT WHEN COMPARED TO MSM ON PrEP (ABSTRACT
184)
Magnus Gisslen
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
CEREBROSPINAL FLUID HIV RNA AND VIRAL NUCLEIC ACID DETECTION IN PERSONS WITH HIV (ABSTRACT
185)
Merle Henderson
Imperial College London, London, United Kingdom
HIV CLINICAL, COMORBID, AND SOCIAL DETERMINANTS OF HEALTH ARE LINKED WITH BRAIN AGING (ABSTRACT
186)
Kalen J. Petersen
Washington University in St Louis, St. Louis, MO, United States
QUESTIONS AND ANSWERS (Part 1)
Serena S. Spudich
Yale University, New Haven, CT, United States
Michael Corley
Weill Cornell Medicine, New York, NY, United States
CHANGES TO MICROGLIAL GENOME STRUCTURE AND FUNCTION IN THE HIV-INFECTED HUMAN BRAIN (ABSTRACT
187)
Amara Plaza-Jennings
Icahn School of Medicine at Mt Sinai, New York, NY, United States
BRAIN AND BEHAVIOR PREDICTORS OF SARS-CoV-2 INFECTION AMONG PEOPLE WITH HIV (ABSTRACT
188)
Robert Paul
University of Missouri St Louis, St. Louis, MO, United States
NO CSF BIOMARKER EVIDENCE OF PERSISTING CNS INFECTION AFTER SARS-CoV-2 INFECTION (ABSTRACT
189)
Arvid Eden
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
CSF & PLASMA SOLUBLE BIOMARKERS IN NEURO-PASC: PRELIMINARY RESULTS FROM COVID MIND (ABSTRACT
190)
Lindsay S. McAlpine
Yale University, New Haven, CT, United States
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
